A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

NCT01705483 PHASE1 TERMINATED

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Details

Lead sponsor	Astellas Pharma Global Development, Inc.
Phase	PHASE1
Status	TERMINATED
Enrolment	21
Start date	Tue Aug 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pharmacokinetics of ASP9853
• Non-hematologic Malignancies

Interventions

• ASP9853
• Docetaxel
• Paclitaxel

Countries

United States